Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$4.85 - $14.39
Previous CloseN/A
Volume226.18K
Average Volume (3M)2.56M
Market Cap
$1.64B
Enterprise Value$1.63B
Total Cash (Recent Filing)$188.26M
Total Debt (Recent Filing)$753.00K
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding128,397,280
10 Day Avg. Volume1,820,513
30 Day Avg. Volume2,561,308
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.47K
Enterprise Value/Ebitda-36.50
Forecast
1Y Price Target
$22.00Price Target Upside63.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PositionA strong cash position supports funding of multiple late‑stage trials, lowering the immediate need for additional capital and helping execution of the development plan.
Indication ExpansionPlans to run two pivotal Phase 3 trials plus a Phase 2b study and to explore chronic cough across multiple interstitial lung diseases broaden the program’s market opportunity and create multiple paths to potential approval.
Regulatory ClarityCompletion of the End‑of‑Phase 2 meeting with the FDA and agreement to use objective full‑day cough frequency as the primary endpoint reduces approval uncertainty and provides a clear regulatory framework for pivotal studies.
Bears Say
Near‑term Catalyst ScarcityNo imminent clinical readouts and maintenance of blinded status for key trials limit visibility on efficacy results and reduce the number of near‑term catalysts for investors.
Regulatory BurdenFDA encouragement to conduct two pivotal trials instead of a single study raises development complexity and could materially increase program costs and operational strain.
Timeline And Cost RiskPrioritizing longer‑duration safety data and a larger Phase 3 program increases trial length and resource requirements, which could delay commercialization and extend investor uncertainty.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $4.85 and its highest was $14.39 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $1.64B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 30 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Mar 17, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.037.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.08.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 128,397,280 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went down -4.468%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (63.33% Upside)
$22.00 (63.33% Upside)
Hedge Fund Trend
Decreased
By 997.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
232.05%
12-Months-Change
Fundamentals
Return on Equity
-25.49%
Trailing 12-Months
Asset Growth
74.59%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed notable progress: a positive End-of-Phase 2 meeting with the FDA, clear Phase III plans and timelines, strong clinical momentum from 2025 data, and a solid cash runway into 2028 to reach key readouts. Key risks include the FDA requirement for a 52-week controlled safety database that delays the 24-week efficacy readout, potential additional DDI requirements if new therapies are approved, uncertainty around orphan designation, and the extended timelines associated with global Phase III execution. On balance, achievements and forward execution plans outweigh the manageable challenges.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$22.00
▲(63.33% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.51% Insiders
14.44% Mutual Funds
57.40% Other Institutional Investors
16.88% Public Companies and
Individual Investors